Skip to content

ENLIGHTEN 2: A Phase III, Randomized, Blinded, Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis (CRS) in Adults

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-506268-15-00
Acronym
LYR-210-2021-005
Enrollment
94
Registered
2023-10-05
Start date
2023-06-05
Completion date
2025-03-24
Last updated
2025-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Rhinosinusitis (CRS) in Adults

Brief summary

The primary endpoint is the change from baseline (CFBL) in the 7-day average composite score of the 3 cardinal symptoms (3CS) of nasal blockage/obstruction/congestion, facial pain/pressure, and anterior/posterior nasal discharge at Week 24 in participant without nasal polyps.

Detailed description

1.CFBL in the 7-day average composite score of 3CS at Week 24, 2.CFBL in the 7-day average CS score of nasal blockage/obstruction/congestion at Week 24, 3.CFBL in the 7-day average CS score of anterior/posterior nasal discharge at Week 24, 4.CFBL in the 7-day average CS score of facial pain/pressure at Week 24, 5.CFBL in the 22-item Sino-Nasal Outcome Test (SNOT-22) total score at Week 24, 6.Rescue treatment through Week 24, 7. CFBL in the percent opacification of the bilateral anterior and posterior ethmoids at Week 20, as determined by 3-D volumetric CT analysis.

Interventions

DRUGDEXAMETHASONE
DRUGLYR-210 System

Sponsors

Lyra Therapeutics Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
The primary endpoint is the change from baseline (CFBL) in the 7-day average composite score of the 3 cardinal symptoms (3CS) of nasal blockage/obstruction/congestion, facial pain/pressure, and anterior/posterior nasal discharge at Week 24 in participant without nasal polyps.

Secondary

MeasureTime frame
1.CFBL in the 7-day average composite score of 3CS at Week 24, 2.CFBL in the 7-day average CS score of nasal blockage/obstruction/congestion at Week 24, 3.CFBL in the 7-day average CS score of anterior/posterior nasal discharge at Week 24, 4.CFBL in the 7-day average CS score of facial pain/pressure at Week 24, 5.CFBL in the 22-item Sino-Nasal Outcome Test (SNOT-22) total score at Week 24, 6.Rescue treatment through Week 24, 7. CFBL in the percent opacification of the bilateral anterior and posterior ethmoids at Week 20, as determined by 3-D volumetric CT analysis.

Countries

Belgium, Bulgaria, Germany, Hungary, Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026